WADA prohibited list is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-07-21. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
For example, the protein DegP plays a role in proteolysis with higher temperatures and is involved in refolding functions at lower temperatures. Lastly, these crystal structures have shown that the second function may negatively affect the first function in some moonlighting proteins. As seen in ƞ-crystallin, the second function of a protein can alter the structure, decreasing the flexibility, which in turn can impair enzymatic activity somewhat.
concentration The quantity or abundance of a constituent of a mixture per unit quantity of that mixture; e.g. the amount, in moles, of a dissolved solute per unit volume of a solution, a measure known as molar concentration or molarity. Several different definitions of concentration are widely used in chemistry, including molar concentration, mass concentration, and volume concentration.
For voluntary and charitable services to the community in Limavady, County Londonderry. David Gregory Snook. Reading Volunteer, Hampton Primary School, Herne Bay, Kent. For services to Education. Versha Sood-Mahindra. Lately Dementia Lead, BUPA. For services to Community Cohesion and to People with Dementia in Cardiff. Zoe Donna Sookun. Project Manager, Network Rail. For services to the Railway and to Rail Aid for Ukraine. Denise Speight. Chargehand Cleaner, Newcastle City Council. For services to Local Government. Charlotte Jessica Stacey. On Call Firefighter, Oxfordshire Fire and Rescue Service. For services to the community in Oxfordshire. Margaret Pearl Sterling. Teaching Associate, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast. For services to Higher Education in Northern Ireland. Eileen Linda Stewart. Manager, Armagh Business Centre. For services to Entrepreneurship, to Economic Regeneration and to the community in Armagh, Northern Ireland. Gloria Ann Stewart. For services to the community in Sheffield, South Yorkshire. Sheena Stewart. Lately Warden, Chalmers Court Sheltered Housing Complex, Inverarary. For services to the community in Mid-Argyll. Allan Stokoe. For services to the community in Eldon, North Yorkshire. Dr Jill Mary Stoner. Chair, Cromarty Care Project. For services to the community in Cromarty, Ross and Cromarty. Jan Tallis. Founding Chair, Community Schools Trust. For services to Children and Families in the London Borough of Newham. Robert Sherwin Taylor. For services to the community in Shipbourne, Kent.
== COVID-19 pandemic == ADLM members who are frontline laboratory specialists also encounter significant challenges in carrying out such studies. Lack of product selection and research materials as well as personal protective equipment, known as PPE, are the most important of these barriers. In recognition of these obstacles to optimizing research ability, ADLM sent a letter to the Coronavirus Task Force advising the Task Force and White House to minimize supply chain issues, and to identify and organize tools such that doctors, nurses, laboratory personnel and other healthcare staff may do their jobs. ADLM has produced instructional videos demonstrating serology, treatment of polymerase chain reaction (PCR), and more through research in the spotlight during the COVID-19 pandemic.
Eventually, the GLP-1 derivatives Mojsov synthesized, without her knowledge were patented as peptides able to prompt the release of insulin, but with Joel Habener as the sole-creator. Mojsov fought to have her name included in patents, with MGH eventually agreeing to amend four patents to include her name and she received her one-third of drug royalties for one year. She has continued to speak up for credit after her collaborators received various awards as new versions of GLP-1 have been approved and grown popular.
Sources: en.wikipedia.org
The sclera, also known as the white of the eye or, in older literature, as the tunica albuginea oculi, is the opaque, fibrous, protective outer layer of the eye containing mainly collagen and some crucial elastic fiber. In the development of the embryo, the sclera is derived from the neural crest. In children, it is thinner and shows some of the underlying pigment, appearing slightly blue. In the elderly, fatty deposits on the sclera can make it appear slightly yellow. People with dark skin can have naturally darkened sclerae, the result of melanin pigmentation. In humans, and some other vertebrates, the whole sclera is white or pale, contrasting with the coloured iris.
Causes disease clinically similar to types II and III, thought to be related to inability of chaperone protein HP47 to unbind from collagen type I, as to do so it needs to bind to the missing ER lumen protein retaining receptor 2 protein encoded by KDELR2. Given the rapid rate of type discovery, it is extremely likely that there are other genes associated with OI that have yet to be reported.
However, new kits such as "NETSPOT" for more rapidly preparing Ga-68 edotreotide or DOTATATE from Ga-68(III) ions have increased the flexibility of sourcing of this radiopharmaceutical for Ga-68 endocrine receptor (octreotide) scans. With NETSPOT the preparation of the Ga-68 DOTATATE is immediate once the Ga-68 has been acquired from the generator and mixed with the reagent.
Disagreements arose, because the brigand wanted to assault Platì and take revenge on the local liberals, unlike Borjes, who eventually gave in. The unsuccessful assault took place on September 17. The brigands and legitimists were repelled by the National Guards and a regular army unit. This failure soon ended their collaboration. On October 20 Borjes traveled to Basilicata to join his forces with those of Carmine Crocco. They achieved successes, but not the final objective, as the brigand leader refused to turn his men into a regular army. Noting the failure of the plan, the Catalan general attempted to travel to Rome to report to the Bourbon ruler. He was captured in Tagliacozzo and shot on 8 December 1861. Borjes' failure did not end brigandage, which continued with greater virulence. For this reason, the first Minghetti government promulgated the Pica law on 15 August 1863. It was a regulation that suspended constitutional guarantees for the southern provinces and imposed a state of siege. It delivered brigands to military tribunals, without appeal or defense. In Calabria the law was applied in Citeriore and Calabria Ulteriore Seconda, while the Reggio area, as was the area around Naples and part of Apulia were exempted. The Pica law remained in force until 31 December 1865, and contributed to eradicating banditry, albeit with repressive methods and without resolving the southern territories' social and economic problems. An underlying issue was latifundium (estates), which were in the hands of a few economic and political elites.
== Medical uses == Liraglutide is an anti-diabetic medication used for the treatment of type 2 diabetes or obesity. Liraglutide (Victoza) is indicated as an adjunct to diet and exercise to improve glycemic control in people aged ten years of age and older with type 2 diabetes; and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Liraglutide (Saxenda) is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in people aged twelve years of age and older with body weight greater than 60 kilograms (130 lb) and obesity; and in adults with overweight in the presence of at least one weight-related comorbid condition.
Sources: en.wikipedia.org
== Epidemiology == Nickel allergy is the most common contact allergy in industrialized countries, affecting around 8% to 19% of adults and 8% to 10% of children. Women are affected 4–10 times as frequently as men. Nickel allergy is estimated to affect 4% of men and 16% of women worldwide. In southern European countries, nickel allergy is more common than in northern countries, 16% versus 10%. The results are similar in the USA.
NHS England confirms that data managed by Synnovis, an organisation that manages blood tests, was stolen in a cyberattack on 3 June. Flights are restored at Manchester Airport, but with delays for passengers scheduled to travel the previous day. Julian Assange leaves the UK after five years held at Belmarsh Prison after reaching a deal with the US to plead guilty to one charge under the Espionage Act instead of the original 18. He will be returned to his native Australia. 25 June 2024 United Kingdom general election betting scandal: The Conservative Party withdraws its support for Craig Williams and Laura Saunders as election candidates. Cabinet minister Alister Jack, who previously said he had won £2,100 by betting on the date of the election, then said he was joking, issues a statement in which he says he did not place a bet on the election. The Metropolitan Police confirms that the Gambling Commission are investigating a further five police officers for placing bets on the date of the election. Russell George, the Senedd member for Montgomeryshire, becomes the fifth Conservative politician to be investigated by the Gambling Commission for election betting. Labour suspends Kevin Craig, their candidate for Central Suffolk and North Ipswich, after the Gambling Commission launches an unrelated investigation into him for placing a bet against himself losing in his constituency. Police arrest four men who entered the grounds of Kirby Sigston Manor, the constituency home of Rishi Sunak.
== History == Marfan syndrome is named after Antoine Marfan, the French pediatrician who first described the condition in 1896 after noticing striking features in a five-year-old girl. The gene linked to the disease was first identified by Francesco Ramirez at the Mount Sinai Medical Center in New York City in 1991.
A small N-terminal domain (160 amino-acid residues) A large C-terminal domain (240 amino-acid residues) Each noncovalently-associated monomer subunit consists of both domains. The subunits interact with each other through about 20 hydrogen bonds and four ion pairs, providing stability to the dimer. The two domains in each monomer subunit are more loosely connected, with only six hydrogen bonds and one ion pair between them, and no intra- or intermolecular disulfide bonds. Looking more closely at the two domains, the following structures were described in 1988:
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.